Clinically, ovarian cancer patients exhibit significantly reduced serum CCL11 levels compared to healthy controls and patients with other malignancies, with these levels inversely correlating with relapse-free survival post resection. This evidence concerns the gene CCL11 and ovarian carcinoma.